Table 3.

Incidence of the adverse drug reaction blepharitis (including allergic response) with ripasudil treatment, by baseline characteristic

Baseline characteristic	Category	n	Blepharitis, n (%)	p value
Sex	Male	1617	114 (7.1)	0.002
	Female	1757	176 (10.0)
Age	< 65 years	1002	108 (10.8)	0.005
	≥ 65 to < 75 years	1156	98 (8.5)
	≥ 75 years	1216	84 (6.9)
Comorbid or a previous history of conjunctivitis	No	2697	210 (7.8)	0.001
	Yes	677	80 (11.8)
Comorbid or a previous history of blepharitis	No	3235	264 (8.2)	< 0.001
	Yes	139	26 (18.7)
Comorbid diabetes mellitus	No	2917	254 (8.7)	0.591
	Yes	457	36 (7.9)
Comorbid hypertension	No	2560	209 (8.2)	0.115
	Yes	814	81 (10.0)
History of pollen allergy	No	2621	210 (8.0)	< 0.001
	Yes	331	46 (13.9)
History of medication allergy	No	2820	232 (8.2)	< 0.001
	Yes	132	24 (18.2)
Number of concomitant pharmaceutical components for glaucoma used	0	348	33 (9.5)	< 0.001
	1	729	70 (9.6)
	2	883	96 (10.9)
	3	915	72 (7.9)
	≥ 4	499	19 (3.8)
Concomitant pharmaceutical components for glaucoma
Prostaglandin analogues	No	641	56 (8.7)	0.876
	Yes	2733	234 (8.6)
β-blockers	No	1251	126 (10.1)	0.022
	Yes	2123	164 (7.7)
CAIs (topical formulation)	No	1917	188 (9.8)	0.004
	Yes	1457	102 (7.0)
α2-agonists	No	2561	243 (9.5)	< 0.001
	Yes	813	47 (5.8)
α1-blockers	No	3334	288 (8.6)	0.576
	Yes	40	2 (5.0)
Parasympathomimetic drugs	No	3340	290 (8.7)	0.113
	Yes	34	0
CAIs (systemic formulation)	No	3291	286 (8.7)	0.318
	Yes	83	4 (4.8)
Others	No	3221	282 (8.8)	0.141
	Yes	153	8 (5.2)
Other concomitant pharmaceutical agents
Anti-allergic drugs	No	3117	253 (8.1)	0.001
	Yes	257	37 (14.4)
Steroidal anti-inflammatory drugs	No	3030	259 (8.6)	0.761
	Yes	344	31 (9.0)
NSAIDs	No	3144	269 (8.6)	0.716
	Yes	230	21 (9.1)
Drug treatments for dry eye	No	2753	246 (8.9)	0.154
	Yes	621	44 (7.1)
Antibiotics	No	3098	266 (8.6)	0.911
	Yes	276	24 (8.7)

CAI carbonic anhydrase inhibitor, NSAID non-steroidal anti-inflammatory drug